Researchers in China have established the Leading Goose Autism Cohort Study, publishing a prospective longitudinal cohort protocol designed to investigate autism spectrum disorder through integrated clinical phenotyping, neuroimaging, and multi-omics profiling. The protocol establishes a comprehensive framework to generate population-specific evidence while addressing critical gaps in neurodevelopmental data integration.
Autism spectrum disorder presents as a complex and heterogeneous neurodevelopmental condition with limited effective treatments. According to the study background, advancements in diagnosis and therapeutic intervention require biologically grounded stratification. However, existing research cohorts have been constrained by fragmented designs and insufficient multimodal data integration, which continue to limit mechanistic insight and precise subtype identification.
To overcome these limitations, the Leading Goose Autism Cohort Study has launched prospective participant recruitment, with data collection officially commencing on May 6, 2025. The study protocol outlines a target enrollment of 3,000 participants aged 1 to 17 years, encompassing a primary cohort of 2,000 children with autism spectrum disorder and a comparison group of 1,000 neurotypical controls.
Enrolled participants are undergoing standardized multimodal data collection protocols designed to capture multidimensional biological and behavioral features. The methodological pipeline integrates detailed clinical phenotyping, neuroimaging examinations, and blood sampling dedicated to comprehensive multi-omics profiling across the cohort.
In addition to individual assessments of the enrolled children, the study design incorporates family-based data collection.
The study protocol outlines an extensive longitudinal schedule to evaluate developmental trajectories over two decades. Standardized follow-up assessments are formally scheduled at intervals of 1, 3, 5, 10, and 20 years following initial participant enrollment.
The authors note that the cohort serves as a comprehensive longitudinal resource for autism research, though long-term objectives including biomarker discovery, enhanced diagnostic strategies, and targeted clinical interventions remain prospective goals requiring future validation. The study was prospectively registered with the Chinese Clinical Trial Registry under registration identifier ChiCTR2500101955.
Subject of Research: Prospective multimodal longitudinal cohort study protocol for autism spectrum disorder in China
Article Title: The leading goose autism cohort study in china with multi-omics, neuroimaging, and clinical phenotyping: a prospective longitudinal cohort study protocol
Article References: Li, C., Wu, Z., Long, J., Luo, Y., Zheng, R., Tan, F., Ma, X., Yu, Y., Ruan, W., Che, Y., Li, E., Li, H., Ma, D., & Zhu, J. (2026). The leading goose autism cohort study in china with multi-omics, neuroimaging, and clinical phenotyping: a prospective longitudinal cohort study protocol. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08854-9
Image Credits: AI Generated
DOI: 10.1186/s12888-026-08854-9
Keywords: autism spectrum disorder, LEGACS, Leading Goose Autism Cohort Study, study protocol, prospective cohort, longitudinal study, multi-omics, neuroimaging, clinical phenotyping, pediatric cohort, neurotypical controls, blood sampling, family-based data, biomarker discovery, subtype identification, Chinese Clinical Trial Registry, BMC Psychiatry
News Source: Phoebe Ingram. (November 12, 2026). Chinese Autism Cohort Study Protocol Outlines Multimodal Longitudinal Tracking in Children. Scienmag.



